Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on I-MAB (IMAB – Research Report) and keeping the price target at $8.00.

Leerink analyst Andrew Berens downgraded Compass Therapeutics (CMPX) to Market Perform from Outperform with a price target of $4, down from $5.

President-elect Donald Trump’s new ally is set to run an outside commission on government efficiency to identify ways to slash government bloat, axe hundreds of thousands of bureaucratic jobs, and cut ...

Wes Streeting has also issued new advice to British travellers seeking treatments abroad in response to reporting by ITV News ...